The role of amplified in breast cancer 1 in breast cancer: A meta-analysis

PURPOSE: Amplified in breast cancer 1 (AIB1) expression is known to be involved in the initiation and progression of malignant breast cancer (BC), but its prognostic role remains uncertain. This meta-analysis assessed reported studies to evaluate this relationship. METHODS: Electronic databases were systematically reviewed to collect eligible studies using pre-established criteria. Hazard ratios (HRs) or odds ratios (ORs) and 95% confidence intervals (CIs) were pooled to estimate the impact of AIB1 protein expression on overall survival (OS) and clinicopathologic properties of BC cases. RESULTS: Nine eligible studies, including 6774 patients, were finally assessed by the current clinical meta-analysis. AIB1 positivity correlated with reduced OS (pooled HR = 1.409, 95% CI 1.159–1.714, P = .001). AIB1 overexpression also impacted prognosis as shown by univariate (pooled HR = 1.420, 95% CI 1.154–1.747, P = .001) and multivariate (pooled HR = 1.446, 95% CI 1.099–1.956; P = .009) analyses. Notably, subgroup analyses also revealed that AIB1 overexpression was associated with poor OS in some subgroups, such as ER-positive group (pooled HR = 1.511, 95% CI 1.138–2.006, P = .004), ER-positive without tamoxifen administration group (pooled HR = 2.338, 95% CI 1.489–3.627, P < .001), and premenopausal women group (pooled HR = 1.715, 95% CI 1.231–2.390, P = .001). Additionally, high AIB1 protein levels were associated with HER2 positivity (pooled OR = 0.331, 95% CI 0.245–0.448; P < .001), poorly differentiated histological grade (pooled OR = 0.377, 95% CI 0.317–0.448; P < .001), high Ki67 (pooled OR = 0.501, 95% CI 0.410–0.612; P < .001), presence of lymph node metastases (pooled OR = 0.866, 95% CI 0.752–0.997; P = .045), and absence of progesterone receptor (pooled OR = 1.447, 95% CI 1.190–1.759; P < .001). CONCLUSIONS: This analysis demonstrated that AIB1 overexpression is related to aggressive phenotypes and unfavorable clinical outcomes in BC, and might involve in tamoxifen resistance. AIB1 may be a new prognostic biomarker and therapeutic target in BC.